Back to top

Analyst Blog

Sanofi (SNY - Analyst Report) recently gained US Food and Drug Administration approval for Auvi-Q (epinephrine injection) for the emergency treatment of life-threatening allergic reactions in patients at risk or with a history of anaphylaxis.

Auvi-Q is a unique epinephrine auto-injector, which guides the patients and physicians through each step of the injection process with the help of audio and visual instructions. While Sanofi will market the drug in the US, Intelliject, Inc. possesses the rights to the drug in rest of the world.

Currently, epinephrine is the only first-line treatment for anaphylaxis. Mylan (MYL - Analyst Report) markets an epinephrine auto-injector, which is used to treat severe allergic reactions like anaphylaxis. Mylan and Pfizer (PFE - Analyst Report) currently have an agreement for EpiPen, under which Pfizer manufactures and Mylan markets the product. The EpiPen Auto-injector is the best prescribed treatment for severe allergic reactions with a US market share of over 95%.

This is the second regulatory approval for Sanofi in the last few days. Earlier this month, the FDA cleared Sanofi and Regeneron Pharmaceuticals’ (REGN - Analyst Report) oncology candidate, Zaltrap. The FDA approved Zaltrap as a combination therapy for treating patients suffering from metastatic colorectal cancer, who are either resistant to or whose disease has progressed following treatment with an oxaliplatin-containing regimen.

Our Recommendation

We expect Sanofi to contain operating costs in order to increase earnings in the face of weakening sales of some of its key drugs. We also expect the company to pursue bolt on acquisitions. We are pleased with the company’s efforts to develop its pipeline.

We currently have a Neutral recommendation on Sanofi. The stock carries a Zacks #3 Rank (Hold rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SYNAPTICS I… SYNA 78.11 +8.14%
CENTURY ALU… CENX 19.88 +5.74%
GREEN PLAIN… GPRE 39.41 +5.12%
PILGRIM'S P… PPC 28.82 +3.08%
THE PANTRY… PTRY 18.41 +2.79%